May 10, 2018
Warning to Eli Lilly's Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to Unseat
Apr 23, 2018
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
Apr 06, 2018
Asia-Pacific Rheumatoid Arthritis (RA) Therapeutics Markets to 2023 - Growth is Expected to Continue at a Moderate Pace from $5.6 Bn in 2016 to $9.5 Bn in 2023
Mar 29, 2018
Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023
Feb 07, 2018
Theravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases
Nov 21, 2017
Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech's RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US
Oct 26, 2017
Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023
Sep 14, 2017
Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
Sep 11, 2017
Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress
Aug 30, 2017
Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018
Jul 25, 2017
Lilly and Incyte Provide Update on Baricitinib
Jun 23, 2017
European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL